Top 25 Countries Allergy Immunotherapies Market 2019-2025 & Competitive Intelligence of Top 10 Companies

Allergy immunotherapy, conjointly stated as desensitization or hypo-sensitization, is a medical treatment targeted for various sorts of allergies. Rise in prevalence of allergy and pharmacotherapy alone is insufficient to regulate the sickness. The allergy immunotherapeutic treatment helps increase immunological tolerance and alters the sickness course. The hypo-sensitization therapy provides long-term impact that extends past the conclusion of treatment. This therapy improves the quality of life of allergic patients.
Allergy Immunotherapy Market was valued at US$ 1.54 Bn in 2018 and expected to grow at 10.9 % Compound Annual Growth Rate (CAGR) over 2019 to 2025. The increasing prevalence of varied sorts of allergies across the world is driving the allergy immunotherapies market. The growing incidence of allergy is generated by factors like increasing pollution and augmented consumption of tobacco product like cigarettes, that is probably going to boost the worldwide allergy immunotherapy market.
The Unknown pathogenesis of varied allergies is that the major challenge faced by the worldwide allergy immunotherapies market. The unclear explanation for allergy ends up in physicians misdiagnosing the allergen, and as a result, the treatment prescribed is not as effective because it ought to be, and it usually ends up in adverse events.
The following companies are the key players in Allergy Immunotherapy Market: There are plenty of large and small market players which operate in this market all over the globe.
·         ALK Abello A/S (Denmark),
·         DBV Technologies (France),
·         Stallergenes Greer (UK),
·         HAL Allergy Group (Netherlands),
·         Allergy Therapeutics (UK),
·         Merck KGaA (Allergopharma) (Germany), and
·         Circassia (UK) among others.

Geographically, the allergy immunotherapy market has been categorised into 5 regions: North America, Europe, Asia Pacific, Latin America, and the Middle East. Europe accounted for the biggest share of the world allergy immunotherapy market in 2018, followed by North America. Europe accounts for an oversized share of the market because of high awareness, increase in funding for research and grants, favourable medical reimbursement policies, the rise in allergic population, and promising clinical pipeline product. The region may be an extremely engaging market and is anticipated to expand at a major CAGR throughout the forecast period. The allergy immunotherapy market in the Asia Pacific is anticipated to expand at a moderate rate of growth. Majority of the market share of allergy immunotherapy is captured by Japan and China in the Asia-Pacific region, because of the presence of a big allergic population in these countries.
Segments for Global Allergy Immunotherapy Market
By allergy type, the global allergy immunotherapy market has been segmented into
·         allergic rhinitis
·         allergic asthma
·         peanut allergy
·         cat allergy
·         other allergies.
 The allergic rhinitis segment currently accounts for a dominant share of the market. Meanwhile, the peanut allergy segment is estimated to register a CAGR of xx %.
By treatment, the allergy immunotherapy market is segmented into
·         Subcutaneous Immunotherapy (SCIT)
·         sublingual immunotherapy
·         Specific Immunotherapy (SIT).

The Subcutaneous Immunotherapy (SCIT) segment holds the largest share of the market and is projected to reach a valuation of USD xx Bn by 2025.

Comments